GRCE · Grace Therapeutics, Inc.
$2.16
+0.01 (+0.47%)
At close · Aug 27
Market Cap
$45.44M
Shares
21.04M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$100M
+50920.4%
FY2022
Gross Margin
100%
+38.8pp
FY2022
Diluted EPS
-$0.47
+40.5%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | $100M | $196K | — | — | — | |
| — | — | — | — | — | $0 | $76K | — | — | — | |
| — | — | — | — | — | $100M | $120K | — | — | — | |
| — | — | — | — | — | 100% | 61.22% | — | — | — | |
| — | — | — | $252K | $661K | $518K | $1.14M | $2.67M | $494K | — | |
| $8.22M | $8.67M | $7.17M | $6.68M | $7.61M | $9.26M | $5.52M | $5.8M | $4.54M | — | |
| — | — | — | — | — | $0 | $781K | $1.91M | $1.95M | — | |
| CAD | — | — | — | — | — | — | — | — | 6.55M | 1.81M |
| $621K | $685K | $711K | $911K | $246K | $77K | $107K | $336K | $358K | — | |
| $1.98M | $1.58M | $3.91M | -$1.83M | $184K | $5.12M | -$3.26M | -$1.08M | -$4.96M | — | |
| -$21.92M | -$9.49M | -$12.77M | -$14.69M | -$51.97M | -$10.47M | -$19.68M | -$25.51M | -$39.37M | — | |
| -$20.22M | -$7.79M | -$9.57M | -$12.85M | — | — | — | — | — | — | |
| USD/shares | -$1.17 | -$0.47 | -$0.79 | -$1.35 | -$5.71 | -$1.62 | — | — | — | — |
| USD/shares | -$1.17 | -$0.47 | -$0.79 | -$1.35 | -$5.71 | -$1.62 | — | — | — | — |
| shares | — | 16.51M | 12.09M | 9.53M | 7.44M | 6.14M | 2.47M | 1.76M | 1.13M | — |
| shares | — | 16.51M | 12.09M | 9.53M | 7.44M | 6.14M | 2.47M | 1.76M | 1.13M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 3.30×
EV/EBIT
—
Peer median 11.76×
P/E (TTM)
—
Peer median 5.80×
Peer medians compare against the 270 similar-size Biotechnology companies (of 517 listed).
Key facts
CIK
1444192
CUSIP
00439U104
13F (30d)
32 filings
32 filers
Visit website
Investor relations